Moneycontrol PRO
Live Now |Super25 3.0- India’s Largest Online Stock Traders Conference brought to you by Moneycontrol Pro & Espresso

Zydus Cadila gets USFDA nod to market anti-ulcer capsules

Shares of Cadila Healthcare were today trading at Rs 654.50 per scrip in the afternoon trade on BSE, up 1.32 percent from its previous close.

August 22, 2013 / 12:22 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Cadila Healthcare today said Zydus Cadila has received final approval from thE US health regulator to market Lansoprazole capsules used for treating ulcers and other conditions involving excessive stomach acid.


Also read: Pharma cos seek customised insurance for legal settlements


"Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Lansoprazole delayed release (DR) Capsules in different strengths of 15 mg and 30 mg," Cadila Healthcare said in a filing to BSE.


The product had estimated sales of USD 501 million in 2012 as per the IMS Health data, it added.


"The group now has 81 approvals and has so far filed 186 abbreviated new drug applications (ANDAs) since the commencement of filing process in FY 2003-2004," Cadila Healthcare said.


Ahmedabad based firm has global operations spread across USA, Europe, Japan, Brazil, South Africa and 25 other emerging markets.

Shares of Cadila Healthcare were today trading at Rs 654.50 per scrip in the afternoon trade on BSE, up 1.32 percent from its previous close.



Download your money calendar for 2022-23 here and keep your dates with your moneybox, investments, taxes

first published: Aug 21, 2013 01:21 pm
Sections
ISO 27001 - BSI Assurance Mark